GlassScriptPhysician profile
Raymond S O'Bryan
NPI 1518429943
$1,108.10
in general payments reported to CMS, 2019-2025
18 companies · $474 in 2025
The $474 reported for 2025 was more than what 82% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
See the full distribution for Sports Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.21 · 2022: $24.49 · 2023: $302 · 2024: $290 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,066.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $184.24 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $170.41 | 2023-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $128.72 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Kowa Pharmaceuticals America, INC. | $118.98 | 2023 | Seglentis |
| Exact Sciences Corporation | $106.19 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $67.76 | 2024-2025 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $48.96 | 2025 | Contrave |
| Amgen INC. | $46.98 | 2024-2025 | Repatha, Otezla, Repatha |
| Pacira Pharmaceuticals Incorporated | $35.38 | 2023 | Iovera, Zilretta, Exparel |
| Merck Sharp & Dohme LLC | $35.34 | 2019-2025 | Gardasil 9, Capvaxive |
| Olympus America INC. | $24.49 | 2022 | |
| Hologic Sales and Service, LLC | $24.41 | 2024 | Aptima, Thinprep 2000 Processor |
| Janssen Pharmaceuticals, INC | $23.73 | 2023 | Spravato |
| Pfizer INC. | $20.47 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.25 | 2025 | Jardiance |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $19.00 | 2024 | Voquezna |
| Sanofi Pasteur INC. | $17.02 | 2023 | |
| Shield Therapeutics INC | $16.77 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond O'Bryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.